Physician profile
Sandra E Lerner
NPI 1225018781
$2,883.31
in general payments reported to CMS, 2019-2025
15 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.00 · 2021: $630 · 2022: $124 · 2023: $193 · 2024: $900 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $916.97 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.00 | 2021 | |
| Lilly USA, LLC | $389.79 | 2022-2025 | Kisunla, Zepbound, Mounjaro |
| Pfizer INC. | $161.47 | 2023-2025 | |
| Abbvie INC. | $156.51 | 2023-2025 | |
| Amgen INC. | $155.11 | 2024-2025 | Repatha, Repatha, Otezla |
| Rhythm Pharmaceuticals, INC. | $110.52 | 2024-2025 | Imcivree |
| Astrazeneca Pharmaceuticals Lp | $102.61 | 2024-2025 | Airsupra |
| Exact Sciences Corporation | $97.35 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $69.03 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $24.00 | 2020 | |
| Corcept Therapeutics | $23.92 | 2025 | Korlym |
| Pharming Healthcare, INC. | $18.64 | 2024 | Ruconest |
| Astellas Pharma US INC | $14.02 | 2025 | Veozah |
| Actelion Pharmaceuticals US, INC. | $13.37 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.